Here we will explore the latest relevant literature from January 2019 to April 2024 in the database PubMed/MEDLINE, with the results enriched by manual searches and citation mining, and discuss the ongoing therapeutic options for MASLD focused on treating T2DM, insulin resistance, and intermediary metabolism to address the global health burden of these highly relevant diseases
Severe GI events that required dose reduction or treatment discontinuation were relatively rare
For patients concerned about the high costs associated with weight loss medications, compounded semaglutide presents a budget-friendly alternative
Ozempic, a GLP-1 medication for type 2 diabetes, contains semaglutide as its active ingredient, the same ingredient found in Wegovy, which is FDA-approved for weight management
Fatigue, headache, dizziness, constipation, and nausea may all feel worse when fluids are low
Market implications The trial's results show that orforglipron, which was developed by Eli Lilly, can be considered one of semaglutide's most credible challengers
